Aktienanalyse zu Cerus Corp (CERS)CERSCerus Corp

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Cerus Corp is currently not a strong buy due to its low price and high risk, but it has potential for recovery. The current price is $2.18, and the RSI is at 21.457, indicating it is oversold. However, the stock has a forward P/E of 0, reflecting uncertainty in earnings recovery. The analyst price target from Freedom Broker is $6.50, suggesting significant upside potential, but the stock has seen a 5-day change of -5.22%, indicating recent weakness. The main risk is the negative sentiment reflected in the recent earnings report, where the stock dropped 25.61% after reporting a GAAP EPS of -$0.01, which aligns with expectations but shows ongoing losses. Investors should monitor for signs of recovery before making a buy decision.

3 analysts cover CERS: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.50.